News Sentiment

HBIO sentiment intelligence

Harvard Bioscience Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 6.14 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-0.2% over one week, +1.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Harvard Bioscience focuses on life science instruments as investors weigh long-term demand

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -0.2% Price digesting
Trend fit Trend inactive 1.0% over four weeks
Fair value -71.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 34
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
TradingView 5
TradingKey 5
GlobeNewswire 4
simplywall.st 3
dars.gov.et 2
Moomoo 2
AD HOC NEWS 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 18
Analyst action 3
Macro sensitivity 1
Regulatory and legal 1
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Ad-hoc-news.de Direct company coverage

Harvard Bioscience focuses on life science instruments as investors weigh long-term demand

Harvard Bioscience (HBIO) is a life science tools company that specializes in preclinical research instruments and laboratory systems. The company's business model relies on selling capital equipment, consumables, and services to pharmaceutical and biotechnology companies, contra

Tone
Neutral 50/100
Event
Macro sensitivity
Published
09 Jul 2026 13:11
Source
Ad-hoc-news.de
Moomoo Direct company coverage

Harvard Bioscience | SD: Specialized disclosure report

This article is a specialized disclosure report from Harvard Bioscience. The content of the report is provided in the document.

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 15:10
Source
Moomoo
TradingView Direct company coverage

Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO)

This article provides an overview of Harvard Bioscience, Inc. (HBIO) stock performance, analyst estimates, and financial data. It covers current stock price, market capitalization, earnings, revenue, and future forecasts. The company's next earnings report is expected on July 30,

Tone
Positive 60/100
Event
Earnings
Published
26 Jun 2026 09:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Harvard Bioscience, Inc. – NASDAQ:HBIO

This article provides a brief snapshot of Harvard Bioscience, Inc. (NASDAQ: HBIO) financial data, specifically focusing on its forward price-to-sales ratio. It appears to be a stub or an outdated page from a financial data platform like TradingView, intended to display financial

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 13:12
Source
TradingView
TradingView Direct company coverage

HBIO Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Harvard Bioscience, Inc. (HBIO) stock, based on analyst opinions. It details current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings reports, along with financial data lik

Tone
Neutral 50/100
Event
Analyst action
Published
23 Jun 2026 17:41
Source
TradingView
TradingKey Direct company coverage

Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis

Harvard Bioscience Inc (HBIO) has a current financial score of 7.02, indicating a weak financial status despite high operating efficiency, ranking 114 out of 203 in its industry. The company's recent quarterly revenue decreased by 4.68% year-over-year to $20.75M, while net profit

Tone
Negative 39/100
Event
Earnings
Published
23 Jun 2026 08:13
Source
TradingKey
AD HOC NEWS Direct company coverage

Harvard Bioscience holds key trading range, shares between support and resistance

Harvard Bioscience (HBIO) is currently trading within a defined range on Nasdaq, with technical analysis indicating support at $5.10 and resistance at $6.65. Despite a relatively solid momentum score, short-term signals are cautious, with more sell than buy indicators reported by

Tone
Neutral 50/100
Event
Regulatory and legal
Published
22 Jun 2026 20:10
Source
AD HOC NEWS
TradingKey Direct company coverage

Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Harvard Bioscience Inc (HBIO), noting its current valuation score is 9.02, ranking it 46 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -2.77, while stating that relevant data for

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 20:10
Source
TradingKey
TradingKey Direct company coverage

Harvard Bioscience Inc (HBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Harvard Bioscience Inc (HBIO), detailing its current price momentum score, support and resistance levels, and indicator readings. It also outlines the stock's moving average status, with a current overall signal of "Sell" based on tec

Tone
Negative 28/100
Event
Market update
Published
18 Jun 2026 10:38
Source
TradingKey
TradingKey Direct company coverage

Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Harvard Bioscience Inc (HBIO), highlighting its current earnings forecast score and analyst ratings. It details the average price target, expected revenue for the next quarter, and historical as well as forecasted EPS. The report ind

Tone
Positive 64/100
Event
Earnings
Published
18 Jun 2026 09:38
Source
TradingKey
TradingKey Direct company coverage

Harvard Bioscience Inc (HBIO) Institutional Confidence

Harvard Bioscience Inc (HBIO) has an institutional shareholding score of 5.00, placing it 109th out of 204 in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 13.62% quarter-over-quarter to 54.17%. James Simons is the largest instit

Tone
Positive 62/100
Event
Market update
Published
18 Jun 2026 09:38
Source
TradingKey
Stock Titan Direct company coverage

Director at Harvard Bioscience (HBIO) granted 16,556 restricted stock units

Harvard Bioscience director Katherine A. Eade was granted 16,556 restricted stock units (RSUs) of common stock at no cost. These RSUs will vest either before the company's next annual meeting or one year from the grant date, whichever comes first. Following this transaction, Eade

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 16:08
Source
Stock Titan
Stock Titan Direct company coverage

Harvard Bioscience (HBIO) director awarded 16,556 restricted stock units

Harvard Bioscience director William Snider was granted 16,556 restricted stock units (RSUs) as compensation, which will vest either before the next annual meeting or one year from the grant date. This award increases his total holdings to 48,556 common share equivalents, includin

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 16:40
Source
Stock Titan
Stock Titan Direct company coverage

Harvard Bioscience (NASDAQ: HBIO) awards director 16,556 RSUs

Harvard Bioscience (NASDAQ: HBIO) director Stephen J. Denelsky was granted 16,556 restricted stock units (RSUs) as reported in a Form 4 SEC filing. These RSUs will vest either immediately before the company's next annual meeting or one year from the grant date, serving as a time-

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 13:39
Source
Stock Titan
Stock Titan Direct company coverage

Director at Harvard Bioscience (HBIO) awarded 16,556 RSUs

Harvard Bioscience director Seth Benjamin Benson was granted 16,556 restricted stock units (RSUs) of common stock at a price of $0.0000 per share. These RSUs will vest either immediately before the company’s next annual meeting or one year from the grant date, whichever comes fir

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 13:39
Source
Stock Titan
Moomoo Direct company coverage

Harvard Bioscience | 8-K: Harvard Bioscience Announces First Quarter 2026 Financial Results

This article is a placeholder indicating that Harvard Bioscience announced its First Quarter 2026 Financial Results via an 8-K filing. The content displayed is merely a document placeholder, suggesting the detailed results would be within the actual 8-K filing.

Tone
Neutral 50/100
Event
Earnings
Published
03 Jun 2026 03:10
Source
Moomoo
Stock Titan Direct company coverage

Harvard Bioscience (NASDAQ: HBIO) shareholders approve equity and ESPP share increases

Harvard Bioscience, Inc. shareholders approved key proposals at their 2026 Annual Meeting, including an increase of 400,000 shares for their 2021 Incentive Plan and amendments to the Employee Stock Purchase Plan. Shareholders also re-elected two Class II directors, ratified Grant

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 20:09
Source
Stock Titan
MSN Direct company coverage

Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12

This article reports that the price target for Harvard Bioscience (HBIO) has been significantly increased by 200.00% to $6.12. No further details are provided in the snippet.

Tone
Positive 76/100
Event
Analyst action
Published
01 Jun 2026 01:39
Source
MSN
Intellectia AI Direct company coverage

HBIO PE Ratio & Valuation, Is HBIO Overvalued

Harvard Bioscience Inc (HBIO) is currently considered to be in the "Fair zone," with its forward PE ratio of 15.06 fairly comparable to its five-year average of 23.52. The fair price for HBIO is estimated to be between $2.40 and $14.02 based on a relative valuation method. While

Tone
Neutral 50/100
Event
Market update
Published
25 May 2026 00:40
Source
Intellectia AI
AD HOC NEWS Direct company coverage

Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story

Harvard Bioscience (HBIO) reported mixed results for Q2 2025, with revenue missing estimates but adjusted earnings matching expectations thanks to improved cash flow and cost control. The company, a small-cap medtech supplier, operates in the life sciences research sector, making

Tone
Neutral 50/100
Event
Earnings
Published
21 May 2026 12:10
Source
AD HOC NEWS
Seeking Alpha Direct company coverage

Harvard Bioscience, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:HBIO) 2026-05-15

Harvard Bioscience, Inc. (NASDAQ:HBIO) published its Q1 2026 earnings call presentation, reporting an EPS of -$0.33, missing estimates by $0.30, and revenue of $20.76M, a 4.68% year-over-year decrease, missing by $445.00K. The article highlights that the slide deck was released i

Tone
Negative 30/100
Event
Earnings
Published
16 May 2026 00:09
Source
Seeking Alpha
Stock Titan Direct company coverage

Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake

Harvard Bioscience (HBIO) investor Adam M. Hutt, as Managing Member of Leviticus Partners, has filed a Schedule 13G/A, disclosing beneficial ownership of 293,676 shares of Common Stock, representing a 6.5% stake in the company. The filing indicates sole voting and dispositive pow

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 May 2026 16:39
Source
Stock Titan
TradingView Direct company coverage

Discontinued operations of Harvard Bioscience, Inc. – FWB:HBI0

The article reports on the discontinued operations of Harvard Bioscience, Inc., traded on the Frankfurt Stock Exchange under the symbol HBI0. It appears to be a financial news brief, likely indicating a change in the company's operational status. The content is brief and serves a

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 23:40
Source
TradingView
Insider Monkey Direct company coverage

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (NASDAQ:HBIO) reported its Q1 2026 earnings, highlighting continued progress in transforming into a translational science market supplier. The company beat earnings expectations with an EPS of $-0.33, against an expected $-0.62, and saw revenue of $20.8 m

Tone
Positive 62/100
Event
Earnings
Published
13 May 2026 12:08
Source
Insider Monkey
KTVB Direct company coverage

Harvard Bioscience: Q1 Earnings Snapshot

Harvard Bioscience Inc. (HBIO) reported a Q1 loss of $3.4 million, or 77 cents per share. Adjusted for certain costs, the loss was 33 cents per share. The medical instruments company also projected Q2 revenue to be between $20.5 million and $22.5 million.

Tone
Negative 36/100
Event
Earnings
Published
13 May 2026 05:09
Source
KTVB
Sahm Direct company coverage

Harvard Bioscience Announces First Quarter 2026 Financial Results

Harvard Bioscience (Nasdaq: HBIO) reported its first-quarter 2026 financial results, with revenues of $20.8 million and a gross margin of 59%. The company is progressing with the consolidation of manufacturing operations and reaffirmed its full-year 2026 financial guidance, antic

Tone
Positive 66/100
Event
Earnings
Published
13 May 2026 04:39
Source
Sahm